A5089841877- SARS-CoV-2 and COVID-19 Research
- Viral gastroenteritis research and epidemiology
- Virus-based gene therapy research
- Viral Infections and Outbreaks Research
- Animal Virus Infections Studies
- Viral Infectious Diseases and Gene Expression in Insects
- COVID-19 Clinical Research Studies
- Influenza Virus Research Studies
- Monoclonal and Polyclonal Antibodies Research
- Virology and Viral Diseases
- Respiratory viral infections research
- Vaccine Coverage and Hesitancy
- Rabies epidemiology and control
- Viral Infections and Vectors
- Disaster Response and Management
- Bacterial Infections and Vaccines
- Pluripotent Stem Cells Research
- COVID-19, Geopolitics, Technology, Migration
- RNA and protein synthesis mechanisms
- Wireless Body Area Networks
- COVID-19 epidemiological studies
- Immunotherapy and Immune Responses
- Neonatal Respiratory Health Research
- Venomous Animal Envenomation and Studies
- Hepatitis B Virus Studies
Ministry of Health of the Russian Federation
2019-2024
Federal Medical-Biological Agency
2023
Gamalei Institute of Epidemiology and Microbiology
2022
Czech Academy of Sciences, Institute of Philosophy
2020
Newron Pharmaceuticals (Italy)
2005
While the world is experiencing another wave of COVID-19 pandemic, global vaccination program hampered by an evident shortage in supply licensed vaccines. In effort to satisfy vaccine demands we developed a new single-dose based on recombinant adenovirus type 26 (rAd26) vector carrying gene for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) glycoprotein - "Sputnik Light".We conducted open label, prospective, non-randomised phase 1/2 trial aimed assess safety,...
Introduction. Many different vaccines for the prevention of COVID-19 have received emergency use approval in shortest possible time. Due to high rate variability pathogen, this study we analyzed structural proteins SARS-CoV-2 virus and compared their protective potential protecting animals from COVID-19. The aim was compare Materials methods. used study. Transgenic mice B6.Cg-Tg(K18-ACE2)2Prlmn/J (F1) were as model animals. Recombinant adenoviral vectors rAd5-S, rAd5-N, rAd5-M immunization...
Introduction. In 2022, the World Health Organization declared monkeypox a public health emergency. The virus (MPV) is part of Orthopoxvirus genus within Poxviridae family. During replication, orthopoxviruses produce two distinct forms viral particles: extracellular enveloped virion (EEV), released via exocytosis, and intracellular mature (IMV), through cell lysis. These differ in surface proteins composition, influencing their immunogenicity infectivity. Aim. To evaluate immunogenic...
To protect young individuals against SARS-CoV-2 infection, we conducted an open-label, prospective, non-randomised dose-escalation Phase 1/2 clinical trial to evaluate the immunogenicity and safety of prime-boost “Sputnik V” vaccine administered at 1/10 1/5 doses adolescents aged 12–17 years. The study began with vaccination older cohort (15-to-17-year-old participants) lower (1/10) dose then expanded whole group (12-to-17-year-old participants). Next, was used according same scheme. Both...
Human-induced airway basal cells (hiBCs) derived from human-induced pluripotent stem (hiPSCs) offer a promising cell model for studying lung diseases, regenerative medicine, and developing new gene therapy methods. We analyzed existing differentiation protocols proposed our own protocol obtaining hiBCs, which involves step-by-step of hiPSCs into definitive endoderm, anterior foregut NKX2.1+ progenitors, cultivation on medium with subsequent sorting using the surface marker CD271 (NGFR)....
Objectives Vaccination remains the most effective response to COVID-19 pandemic. Most vaccines use two-dose regimens. In turn, single-dose also have high potential, since, on one hand, they simplify vaccination program, make it more accessible and convenient for people around world, other are better suited subsequent revaccination. However, there is not enough data effectiveness of vaccine variants against new genetic lines assess their current potential. It clear how much a single dose...
Ebola fever is an acute, highly contagious viral disease with a mortality rate that can reach 90%. There are currently no licensed therapeutic agents specific to in the world. Monoclonal antibodies (MAbs) viral-neutralizing activity and high specificity virus glycoprotein (EBOV GP) considered as effective potential antiviral drugs. Over past decade, nanobodies (single-domain antibodies, non-canonical camelid antibodies) have found wide use diagnosis treatment of various infectious...
The influenza virus infection claims ~650,000 lives annually. Taking into account the evolving resistance of pathogen to antiviral drugs and waning effectiveness vaccination among certain populations, new approaches treatment are needed. current study is aimed at obtaining single-domain antibodies (Nanobodies) highly conserved stem domain A hemagglutinin by phage display. Two high-affinity neutralizing clones Nanobodies with a particular specificity were selected; they ensured 100%...
Гинцбург А
The continued evolution of influenza viruses reduces the effectiveness vaccination and antiviral drugs. identification novel universal agents for prophylaxis treatment is an urgent need. We have previously described two potent single-domain antibodies (VHH), G2.3 H1.2, which bind to stem domain hemagglutinin efficiently neutralize H1N1 H5N2 in vivo. In this study, we modified these VHHs with Fc-fragment enhance their activity. Reformatting into bivalent Fc-fusion molecule increased its vitro...
The Middle East Respiratory Syndrome (MERS) is an acute inflammatory disease of the respiratory system caused by MERS-CoV coronavirus. mortality rate for MERS about 34.5%. Due to its high rate, lack therapeutic and prophylactic agents, continuing threat spread beyond current confines, developing a vaccine pressing task, because vaccination would help limit reduce death toll. We have developed combined vector prevention based on recombinant human adenovirus serotypes 26 5. Studies...
Technological versatility and the humoral cellular immune response induction capacity have conditioned wide spread of adenoviral vectors as vaccine gene therapy drugs. However, vaccination with Sputnik V made a significant portion population to types 5 26 (Ad5 Ad26) recombinant human adenovirus vectors, which are some most frequently used bases for candidate vaccines. Today, designers tend select alternative serotypes platforms develop vaccines against new pathogens on. A good example is...
The Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in 2012 during the first (MERS) outbreaks. MERS-CoV causes an acute lower-respiratory infection humans, with a fatality rate of ~35.5%. Currently, there are no registered vaccines or means therapeutic protection against MERS world. S glycoprotein plays most important role viral life cycle (virus internalization). protein is immunodominant antigen and main target for neutralizing antibodies. In present study,...
Background: While the world is experiencing another wave of COVID-19 pandemic, global vaccination program hampered by obvious shortage in supply licensed vaccines. Development new vaccines that are easy to manufacture and administer highly desirable overcome hurdles vaccine scaling up distribution, especially developing countries. In effort satisfy demands we developed a single dose based on recombinant adenovirus type 26 (rAd26) vector carrying gene for severe acute respiratory syndrome...
The SARS-CoV-2 virus continuously acquires mutations, leading to the emergence of new variants. Notably, effectiveness global vaccination efforts has significantly declined with rise and spread B.1.1.529 (Omicron) variant.
INTRODUCTION. Marburg and Ebola viruses cause severe haemorrhagic fever in humans primates. Currently, there are no licensed prophylactic vaccines that can simultaneously prevent the spread or reduce severity of both diseases caused by these filoviruses. The development effective requires studies aimed at selecting most immunogenic forms protective antigens. AIM. This study to evaluate humoral immune induction animals after administration recombinant adenoviral vectors expressing various...
Introduction. Recombinant adenoviruses are widely used in the development of vaccines for a variety infectious diseases. Despite numerous clinical studies, only few types human (types 5 and 26) simian (isolate Y25) currently to produce vaccine formulations. Different vary their cellular tropism, which plays key role ability elicit an immune response. The aim this study was investigate tropism adenovirus type 25 vitro its biodistribution vivo comparison with 26. Materials methods. efficiency...
Sputnik V 疫苗接种后志愿者中 SARS-CoV-2 病毒 IgG 特异性抗体与腺病毒 中和抗体效价之间的相关性 Correlation between the titer of
Background: The use of adenoviral vector vaccines is an effective way to induce antiviral immune response. Most used worldwide are based on human adenovirus type 5 (Ad5). Pre-existing natural immunity Ad5 a limitation the frequent Ad5-based vectors in gene therapy and vaccination. In present study, we assessed seroprevalence cross-reactivity neutralizing antibodies six types: Ad1, Ad2, Ad5, Ad19, Ad26, Ad37. Methods: study immunological virological research methods. Adenovirus encoding...